दिशावर

Aug 19, 2025read the full text of arbutus biopharma corporation v. Jun 2, 2022plaintiff arbutus biopharma corporation's responses and objections to defendants moderna, inc. And modernatx inc.'s first set of interrogatories (nos.

17. filed by arbutus biopharma. Apr 3, 202422-252 - arbutus biopharma corporation et al v. Et al summary document in context

Sep 5, 2025arbutus’ patent dispute with moderna is nearing trial. In anticipation of that, the parties have exchanged cross-motions for summary judgment seeking to limit the issues to be heard at trial. Apr 3, 2024computerized translations are only an approximation of the website's original content.

Feb 28, 2022plaintiffs' brief in support of motions in limine filed by arbutus biopharma corporation, genevant sciences gmbh. (hoeschen, nathan) proposed pretrial order by arbutus biopharma. Apr 3, 2024in contrast, moderna argues that such a construction fails to give substance to the word “fully,” which must be interpreted to have some meaning.

According to moderna, the use of the term. And now, this 19th day of november, 2024, the court having considered the parties' stipulation to extend time (d.i. 414), it is hereby ordered that the .

Dec 11, 2025arbutus and genevant have filed motions for summary judgment in the moderna case, and moderna has also filed counter motions. The outcome of these motions, along with rulings on. Der september 2025 könnte für arbutus biopharma zur alles entscheidenden weichenstellung werden.

Der kleine biotech-konzern steht im größten patentstreit seiner geschichte - und es geht um nichts.